natgillin/translations-raw huggingface dataset:
- Fast or uneven heartbeat - High blood pressure - Fits (seizures) - Liver disorders (yellow skin, yellowing of the whites of the eyes, abnormal darkening of the urine or unexplained nausea, vomiting, tiredness and loss of appetite) - Changes in tests which show how well the liver is working - Feeling restless 
- jetrne motnje (porumenelost kože, porumenelost očesnih beločnicm nenormalno temen urin ali nepojasnjena slabost v želodcu, bruhanje, utrujenost in izguba apetita) - spremembe v izvidih preiskav za oceno delovanja jeter
- Rivastigmine 3M Health Care Ltd. 4.6 mg/24 h transdermal patches: Each patch releases 4.6 mg of rivastigmine per 24 hours, is 4.15 cm2 and contains 7.17 mg of rivastigmine. 
- Rivastigmin 3M Health Care Ltd. 4,6 mg/24 h transdermalni obliži: en obliž sprosti 4,6 mg rivastigmina na 24 ur, je velik 4,15 cm2 in vsebuje 7,17 mg rivastigmina.
- Store in the original package in order to protect from light. 
- Shranjujte v originalni ovojnini za zagotovitev zaščite pred svetlobo.
- Rivastigmine 3M Health Care Ltd. 9.5 mg/24 h transdermal patches: Each patch releases 9.5 mg of rivastigmine per 24 hours, is 8.3 cm2 and contains 14.33 mg of rivastigmine. 
- Rivastigmin 3M Health Care Ltd. 9,5 mg/24 h transdermalni obliži: en obliž sprosti 9,5 mg rivastigmina na 24 ur, je velik 8,3 cm2 in vsebuje 14,33 mg rivastigmina.
- Hepatic impairment: No dose adjustment is necessary for patients with hepatic impairment. 
- Okvara ledvic: Pri bolnikih z okvaro ledvic ni potrebno prilagajati odmerjanja.
Store in the original package in order to protect from light. 
Shranjujte v originali ovojnini za zagotovitev zaščite pred svetlobo.
- Renal impairment: Patients with clinically significant renal impairment might experience more adverse reactions (see sections 4.2 and 5.2). 
- Okvara ledvic: Pri bolnikih s klinično pomembno okvaro ledvic je lahko število neželenih učinkov večje (glejte poglavji 4.2 in 5.2).
You may become dehydrated (losing too much fluid) if vomiting or diarrhoea are prolonged. 
Če bruhanje ali driska trajata dolgo, lahko postanete dehidrirani (izgubite preveč tekočine),
The inter-patient variability in a steady-state study in Alzheimer's dementia was at most 45% (Cmax) and 43% (AUC0-24h) after use of the transdermal patch, and 71% and 73%, respectively, after administration of the oral form. 
Interindividualna variabilnost v študiji dinamičnega ravnovesja pri bolnikih z Alzheimerjevo demenco je bila največ 45% za Cmax in 43% za AUC0-24h po uporabi transdermalnega obliža v primerjavi z 71% za Cmax in 73% za AUC0-24h po aplikaciji peroralne oblike.
STATEMENT OF ACTIVE SUBSTANCE(S) 1 transdermal patch of 8.3 cm2 contains 14.33 mg rivastigmine and delivers 9.5 mg/24 h. 
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN 1 transdermalni obliž velikosti 8,3 cm2 vsebuje 14,33 mg rivastigmina in sprosti 9,5 mg/24 h.
The 48-week results for the two assessment tools are summarised in Table 4. 
48-tedenski rezultati teh dveh metod ocenjevanja so
Although less pronounced than with the oral formulation, exposure to rivastigmine (Cmax and AUC) increased over-proportionally by a factor of 2.6 and 4.9 when escalating from 4.6 mg/24 h to 9.5 mg/24 h and to 13.3 mg/24 h, respectively. 
Čeprav manj izrazito kot pri peroralnem odmerjanju, se je pri stopnjevanju z odmerka 4,6 mg/24 h na 9,5 mg/24 h oziroma na 13,3 mg/24 h izpostavljenost rivastigminu (Cmax in AUC) nesorazmerno povečala za faktor 2,6 oziroma 4,9.
- Then press the patch firmly in place for at least 30 seconds using the palm of the hand to make sure that the edges stick well. 
- Nato obliž z dlanjo čvrsto pritiskajte na kožo najmanj 30 sekund, da se robovi obliža dobro prilepijo.
Most skin reactions were limited to the application site and resulted in discontinuation in only 2.4% of the patients in the rivastigmine 9.5 mg/24 h transdermal patch group. 
Zaradi kožnih reakcij je zdravljenje prekinilo le 2,4 % bolnikov v skupini s transdermalnimi obliži z
- Hepatic impairment: Patients with clinically significant hepatic impairment might experience more adverse reactions (see sections 4.2 and 5.2). 
- Okvara jeter: Pri bolnikih s klinično pomembno okvaro jeter je lahko število neželenih učinkov večje (glejte poglavji 4.2 in 5.2).
To prevent interference with the adhesive properties of the transdermal patch, no cream, lotion or powder should be applied to the skin area where the medicinal product is to be applied. 
Da ne bi vplivali na lepljivost transdermalnega obliža, se na predel kože, ki je predviden za namestitev transdermalnega obliža, ne sme nanašati kreme, losijona ali pudra.
- Keep this medicine out of the sight and reach of children. 
- Zdravilo shranjujte nedosegljivo otrokom!
- Only wear one Rivastigmine 3M Health Care Ltd. patch at a time and replace the patch with a new one after 24 hours. 
- Nosite samo en transdermalni obliž Rivastigmin 3M Health Care Ltd. naenkrat in ga po 24 urah
What Rivastigmine 3M Health Care Ltd. looks like and contents of the pack The transdermal patches are rectangular with rounded corners, approximately 2.5 cm by 1.8 cm (Rivastigmine 3M Health Care Ltd. 4.6 mg/24 h transdermal patch) or 3.5 cm by 2.6 cm (Rivastigmine 3M Health Care Ltd. 9.5 mg/24 h transdermal patch). 
Izgled zdravila Rivastigmin 3M Health Care Ltd. in vsebina pakiranja Pravokotni, približno 2,5 cm krat 1,8 cm (Rivastigmin 3M Health Care Ltd. 4,6 mg/24 h transdermalni obliž) ali 3,5 cm krat 2,6 cm (Rivastigmin 3M Health Care Ltd. 9,5 mg/24 h transdermalni obliž) veliki transdermalni obliži z zaobljenimi vogali.
- The other ingredients are polyester, ethyl vinyl acetate, acrylate copolymer adhesive and isopropyl myristate. 
- Druge sestavine zdravila so poliester, etilvinilacetat, adhezivni akrilatni kopolimer in
The single-dose inter-subject variability in rivastigmine pharmacokinetic parameters (normalised to dose/kg bodyweight) was 43% (Cmax) and 49% (AUC0-24h) after transdermal administration versus 74% and 103%, respectively, after the oral form. 
Pri enkratnem odmerjanju je bila interindividualna variabilnost farmakokinetičnih parametrov rivastigmina (normalizirana na odmerek/kg telesne mase) 43 % za Cmax in 49 % za AUC0-24h pri transdermalni aplikaciji v primerjavi s 74 % za Cmax in 103 % za AUC0-24h pri uporabi peroralne oblike.
Application site skin reactions (usually mild to moderate application site erythema), are the most frequent adverse reactions observed with the use of rivastigmine transdermal patch. 
Med neželenimi učinki, ki so jih opažali pri uporabi transdermalnega obliža z rivastigminom, so najbolj pogoste kožne reakcije na mestu apliciranja (običajno blaga do zmerna rdečina kože na mestu apliciranja).
Contact with the eyes should be avoided after handling Rivastigmine 3M Health Care Ltd. transdermal patches (see section 5.3). 
Po rokovanju s transdermalnimi obliži Rivastigmin 3M Health Care Ltd. se ne sme dotikati oči (glejte poglavje 5.3).
STATEMENT OF ACTIVE SUBSTANCE(S) 1 transdermal patch of 4.15 cm2 contains 7.17 mg rivastigmine and delivers 4.6 mg/24 h. 
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN 1 transdermalni obliž velikosti 4,15 cm2 vsebuje 7,17 mg rivastigmina in sprosti 4,6 mg/24 h.
The active substance of Rivastigmine 3M Health Care Ltd. is rivastigmine. 
Zdravilna učinkovina v zdravilu Rivastigmin 3M Health Care Ltd. je rivastigmin.
- The patch should be pressed down firmly for at least 30 seconds using the palm of the hand until the edges stick well. 
- Obliž je treba z dlanjo čvrsto pritiskati na kožo najmanj 30 sekund, dokler se robovi dobro ne
Other medicines and Rivastigmine 3M Health Care Ltd. 
Druga zdravila in zdravilo Rivastigmin 3M Health Care Ltd.
Very rare (may affect up to 1 in 10,000 people) - High blood pressure - Inflammation of the pancreas - the signs include serious upper stomach pain, often with feeling sick (nausea) or being sick (vomiting) - Bleeding in the gut - shows as blood in stools or when being sick - Seeing things that are not there (hallucinations) - Some people who have been violently sick have had tearing of the tube that connects your mouth with your stomach (oesophagus) 
- vnetje trebušne slinavke- med znaki so hude bolečine v zgornjem delu trebuha, pogosto skupaj z občutkom slabosti (navzeo) ali bruhanjem - krvavitev iz črevesja - kaže se kot kri v blatu ali pri bruhanju - vidna zaznava nečesa, česar v resnici ni tam (halucinacije) - pri nekaterih ljudeh je zaradi močnega bruhanja prišlo do raztrganja požiralnika (cevi, ki leži med usti in želodcem)
EXP 
ADL
If you forget to use Rivastigmine 3M Health Care Ltd. 
Če ste pozabili uporabiti zdravilo Rivastigmin 3M Health Care Ltd.
Hands should be washed with soap and water after removing the patch. 
Po odstranjevanju obliža je treba roke umiti z milom in vodo.
No evidence of carcinogenicity was found in oral and topical studies in mice and in an oral study in rats at the maximum tolerated dose. 
V raziskavah peroralnega in lokalnega odmerjanja na miših in raziskavah peroralnega odmerjanja na podganah pri največjem odmerku, ki so ga živali še prenašale, niso opazili nobenih znakov kancerogenosti.
Compared to a patient with a body weight of 65 kg, the rivastigmine steady-state concentrations in a patient with a body weight of 35 kg would be approximately doubled, while for a patient with a body weight of 100 kg the concentrations would be approximately halved. 
V stanju dinamičnega ravnovesja so koncentracije pri bolniku s telesno maso 35 kg približno dvakrat tolikšne kot pri bolniku s telesno maso 65 kg, pri bolniku s telesno maso 100 kg pa pol manjše kot pri bolniku s telesno maso 65 kg. Zaradi vpliva telesne mase na izpostavljenost zdravilni učinkovini je potrebna posebna pozornost pri postopnem zviševanju odmerka bolnikom z zelo majhno telesno maso (glejte poglavje 4.4).
In case the adhesive residue is left over on your skin, gently soak the area with warm water and mild soap or use baby oil to remove it. Alcohol or other dissolving liquids (nail polish remover or other solvents) should not be used. 
Če na koži ostane nekaj lepila, lepljivi predel kože navlažite s toplo raztopino blagega mila ali pa ostanke lepila odstranite z otroškim oljem.
Other side effects seen with Rivastigmine 3M Health Care Ltd. capsules or oral solution and which may occur with the patch: 
Drugi neželeni učinki, ki so jih opažali pri uporabi kapsul ali peroralne raztopine Rivastigmin 3M Health Care Ltd. in bi se lahko pojavili tudi pri uporabi obližev:
The most commonly reported skin irritation events during the first 24 weeks of the double-blind period with rivastigmine 13.3 mg/24 h transdermal patches and rivastigmine 9.5 mg/24 h transdermal patches, respectively were application site erythema (5.7% vs 4.6%) and application site pruritus (3.6% vs 2.8%). 
Najbolj pogoste oblike kožnih reakcij, o katerih so poročali v prvih 24 tednih dvojno slepega obdobja s transdermalnimi obliži z rivastigminom 13,3 mg/24 h in s transdermalnimi obliži z rivastigminom 9,5 mg/24 h, so bile rdečina na mestu aplikacije (5,7% v primerjavi s 4,6%) in srbenje na mestu aplikacije (3,6% v primerjavi z 2,8%).
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON 
PODATKI NA ZUNANJI OVOJNINI ŠKATLICA
- to patients with sick sinus syndrome or conduction defects (sino-atrial block, atrio-ventricular block) (see section 4.8) - to patients with active gastric or duodenal ulcers or patients predisposed to these conditions because rivastigmine may cause increased gastric secretions (see section 4.8) - to patients predisposed to urinary obstruction and seizures because cholinomimetics may induce or exacerbate these diseases. 
atrioventrikularni blok) (glejte poglavje 4.8) - bolnikom z aktivnimi razjedami želodca ali dvanajstnika ali bolnikom z nagnjenostjo k tem boleznim, ker rivastigmin lahko povzroči povečano izločanje želodčne kisline (glejte
Skin application site reactions may occur with rivastigmine patch and are usually mild or moderate in intensity. 
Pri uporabi transdermalnega obliža z rivastigminom lahko na koži pride do reakcij na mestu apliciranja, ki so običajno blago do zmerno izražene.
Consider using the 4.6 mg/24 h transdermal patch both as initial and maximum dose in these patients. 
Pri teh bolnikih velja razmisliti o tem, da je začetni odmerek 4,6 mg/24 h za njih lahko tudi najvišji odmerek.
Uncommon (may affect up to 1 in 100 people) - Uneven heart rate (e.g. fast heart rate) - Difficulty sleeping - Accidental falls 
Občasni (pojavijo se lahko pri največ 1 od 100 bolnikov) - neredno bitje srca (npr. hitro bitje srca)
- If you get any side effects, talk to your doctor, pharmacist or nurse. 
- Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom, farmacevtom ali z medicinsko sestro.
- A patient on a stable and well tolerated dose of 9 mg/day oral rivastigmine can be switched to 
- Bolnik, ki jemlje rivastigmin peroralno v odmerku 6 mg/dan, lahko preide na zdravljenje s
Hepatic impairment 
Prebavne motnje
Overdose with rivastigmine transdermal patches resulting from misuse/dosing errors (application of multiple patches at a time) has been reported in the post-marketing setting. 
V obdobju trženja zdravila so poročali o prevelikem odmerjanju s transdermalnimi obliži z rivastigminom, do česar je prišlo zaradi nepravilne uporabe/odmerjanja (nameščenih več obližev hkrati).
Marketing Authorisation Holder 3M Health Care Limited, 1 Morley Street, 
3M Health Care Limited, 1 Morley Street, Loughborough,
You should wash your hands with soap and water after removing the patch. 
Po odstranjevanju obliža si morate roke umiti z milom in vodo.
Age had no impact on the exposure to rivastigmine in Alzheimer's disease patients treated with rivastigmine transdermal patches. 
Pri bolnikih z Alzheimerjevo boleznijo, ki so jih zdravili s transdermalnimi obliži z rivastigminom, starost ni vplivala na izpostavljenost rivastigminu.
If it helps you, you may write, for example, the day of the week, on the patch with a thin ball point pen. 
Na obliž lahko s tankim kemičnim svinčnikom napišete na primer
IMPORTANT: - Take off the previous patch before putting ONE new patch on. - Only one patch per day. 
POMEMBNO: - Najprej odstranite prejšnji obliž in šele nato namestite EN nov obliž.
Dose escalation 
Zviševanje odmerka
How to apply your Rivastigmine 3M Health Care Ltd. transdermal patch Rivastigmine 3M Health Care Ltd. patches are transparent to translucent, plastic patches that stick to the skin. 
Obliži Rivastigmin 3M Health Care Ltd. so prozorni ali prosojni plastični obliži, ki jih prilepite na kožo.
Package Leaflet: Information for the user Rivastigmine 3M Health Care Ltd. 4.6 mg/24 h transdermal patch Rivastigmine 3M Health Care Ltd. 9.5 mg/24 h transdermal patch rivastigmine 
Navodilo za uporabo Rivastigmin 3M Health Care Ltd. 4,6 mg/24 h transdermalni obliž Rivastigmin 3M Health Care Ltd. 9,5 mg/24 h transdermalni obliž rivastigmin
PHARMACEUTICAL FORM 
IME ZDRAVILA
• Take off the previous patch before putting ONE new patch on. 
• Najprej odstranite prejšnji obliž in šele nato namestite EN nov obliž.
No specific interaction studies have been performed with Rivastigmine 3M Health Care Ltd. transdermal patches. 
S transdermalnimi obliži Rivastigmin 3M Health Care Ltd. niso izvedli specifičnih študij medsebojnega delovanja.
No study was conducted with rivastigmine transdermal patches in subjects with renal impairment. 
Pri osebah z okvaro ledvic niso opravili nobene študije s transdermalnimi obliži z rivastigminom.
- to patients with a history of asthma or obstructive pulmonary disease. 
- bolnikom, ki so nagnjeni k zapori sečnih izvodil in k epileptičnim napadom, ker holinomimetiki lahko sprožijo te bolezni ali njihovo poslabšanje - bolnikom z anamnezo astme ali obstruktivne pljučne bolezni.
Unchanged rivastigmine is found in trace amounts in the urine; renal excretion of the metabolites is the major route of elimination after transdermal patch administration. 
Nespremenjeni rivastigmin najdemo v urinu samo v sledovih.
After a minimum of four weeks of treatment and if well tolerated according to the treating physician, the dose of 4.6 mg/24 h should be increased to 9.5 mg/24 h, the daily recommended effective dose, which should be continued for as long as the patient continues to demonstrate therapeutic benefit. 
Če bolnik ta odmerek po presoji lečečega zdravnika dobro prenaša, je treba po najmanj štirih tednih odmerek 4,6 mg/24 h zvišati na 9,5 mg/24 h, kar je priporočeni dnevni učinkoviti odmerek.
Rivastigmine 3M Health Care Ltd. 4.6 mg/24 h transdermal patch rivastigmine 
Rivastigmin 3M Health Care Ltd. 4,6 mg/24 h transdermalni obliž rivastigmin
Urinary tract infection Metabolism and nutrition disorders Common 
- urinska inkontinenca (nezmožnost zadrževanja urina)
No untoward effects on cardiac conduction were observed following concomitant administration of digoxin and oral rivastigmine. 
Pri sočasni uporabi digoksina in peroralnega rivastigmina niso opazili neželenih učinkov na srčno prevodnost.
INFORMATION IN BRAILLE Rivastigmine 3M Health Care Ltd. 9.5 mg/24 h 
Rivastigmin 3M Health Care Ltd. 9,5 mg/24 h
How to store Rivastigmine 3M Health Care Ltd. 
Kako jemati zdravilo Rivastigmin 3M Health Care Ltd.
The percentages decreased in both rivastigmine 13.3 mg/24 h transdermal patch and rivastigmine 9.5 mg/24 h transdermal patch treatment groups over time (>24 weeks): application site erythema (0.8% vs. 1.6%) and application site pruritus (0.4% vs. 1.2%), respectively. 
Odstotek bolnikov z navedenimi težavami se je sčasoma ( po več kot 24-tedenski uporabi) znižal tako v skupini, v kateri so uporabljali transdermalni obliž z rivastigminom 13,3 mg/24 h, kot tudi v skupini, v kateri so uporabljali transdermalni obliž z rivastigminom 9,5 mg/24 h: rdečina na mestu aplikacije (0,8 % v primerjavi z 1,6 %) in srbenje na mestu aplikacije (0,4 % v primerjavi z 1,2 %).
• Press the patch firmly in place for at least 30 seconds using the palm of the hand. 
• Obliž z dlanjo čvrsto pritiskajte na kožo najmanj 30 sekund.
Rivastigmine 3M Health Care Ltd. is used for the treatment of adult patients with mild to moderately severe Alzheimer's dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour. 
Zdravilo Rivastigmin 3M Health Care Ltd. uporabljamo za zdravljenje odraslih bolnikov z blago do zmerno hudo Alzheimerjevo demenco.
- Do not cut the patch into pieces. 
- Samo en obliž na dan. - Obliža ne smete rezati na manjše dele.
Rivastigmine 9.5 mg/24 h 
Rivastigm in 9,5 mg/24 h n povpre čje
Aggression 
Rivastigmin
You should not breast-feed during treatment with Rivastigmine 3M Health Care Ltd. transdermal patches. 
Med zdravljenjem s transdermalnimi obliži Rivastigmin 3M Health Care Ltd. ne smete dojiti.
NAP226-90) and bodyweight was observed in Alzheimer's dementia patients. 
Pri bolnikih z Alzheimerjevo demenco so opazovali razmerje med telesno maso in izpostavljenostjo zdravilni učinkovini (rivastigminu in presnovku NAP226-90) v stanju dinamičnega ravnovesja.
No study was conducted with rivastigmine transdermal patches in subjects with hepatic impairment. 
Pri osebah z okvaro jeter niso opravili nobene študije s transdermalnimi obliži z rivastigminom.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Rivastigmine 3M Health Care Ltd. 9.5 mg/24 h transdermal patch rivastigmine 
IME ZDRAVILA IN POT(I) UPORABE Rivastigmin 3M Health Care Ltd. 9,5 mg/24 h transdermalni obliž
- Treatment usually starts with Rivastigmine 3M Health Care Ltd. 4.6 mg/24 h. - The recommended daily dose is Rivastigmine 3M Health Care Ltd. 9.5 mg/24 h. If well tolerated, the treating physician may consider increasing the dose to 13.3 mg/24 h (this high strength is currently not available from 3M but may be available from other Marketing 
- Zdravljenje se običajno začne z obližem Rivastigmin 3M Health Care Ltd. 4,6 mg/24 h. - Priporočeni običajni dnevni odmerek zdravila Rivastigmin 3M Health Care Ltd. je 9,5 mg/24 h.
INFORMATION IN BRAILLE Rivastigmine 3M Health Care Ltd. 4.6 mg/24 h 
Rivastigmin 3M Health Care Ltd. 4,6 mg/24 h
Application site skin reactions (e.g. application site erythema, application site pruritus, application site oedema, application site dermatitis, application site irritation), asthenic conditions (e.g. fatigue, 
Bolezni sečil pogosti urinska inkontinenca Splošne težave in spremembe na mestu aplikacije pogosti kožne reakcije na mestu aplikacije (npr. rdečina na mestu aplikacije, srbenje na mestu aplikacije, oteklina na mestu aplikacije, dermatitis na mestu aplikacije, draženje na mestu aplikacije), astenična stanja (npr. utrujenost, astenija), zvišana telesna temperatura, zmanjšanje telesne mase redki padec
ADAS-cog scores: A negative difference in DLSM indicates greater improvement in Rivastigmine 13.3 mg/24 h as compared to Rivastigmine 9.5 mg/24 h. 
DLSM - razlika po metodi najmanjših kvadratov (angl. difference in least square means) LOCF - metoda prenosa zadnje ocene naprej (angl. Last Observation Carried Forward) ocene pri lestvici ADAS-cog: negativna vrednost razlike po metodi najmanjših kvadratov pomeni večje izboljšanje pri uporabi obliža Rivastigmin 13,3 mg/24 h kot pri uporabi obliža Rivastigmin 9,5 mg/24 h. ocene pri lestvici ADCS-IADL: pozitivna vrednost razlike po metodi najmanjših kvadratov pomeni večje izboljšanje pri uporabi obliža Rivastigmin 13,3 mg/24 h kot pri uporabi obliža Rivastigmin 9,5 mg/24 h.
Only one patch should be worn at a time (see section 4.9). 
Nameščen sme biti samo en obliž naenkrat (glejte
- Press the patch firmly in place for at least 30 seconds using the palm of the hand. 
- Obliž z dlanjo čvrsto pritiskajte na kožo najmanj 30 sekund.
The patient's weight should be monitored during therapy with Rivastigmine 3M Health Care Ltd. transdermal patches. 
Med zdravljenjem s transdermalnimi obliži Rivastigmin 3M Health Care Ltd. je treba spremljati bolnikovo telesno maso.
Skin application site reactions 
Večina kožnih reakcij je bila omejena na mesto aplikacije.
NAME OF THE MEDICINAL PRODUCT Rivastigmine 3M Health Care Ltd. 9.5 mg/24 h transdermal patch rivastigmine 
IME ZDRAVILA Rivastigmin 3M Health Care Ltd. 9,5 mg/24 h transdermalni obliž
NAME OF THE MEDICINAL PRODUCT Rivastigmine 3M Health Care Ltd. 4.6 mg/24 h transdermal patch rivastigmine 
IME ZDRAVILA Rivastigmin 3M Health Care Ltd. 4,6 mg/24 h transdermalni obliž
Rivastigmine 13.3 mg/24 h N = 265 
Rivastigmin transdermalni obliži 9,5 mg/24 h N = 251
BATCH NUMBER 
vrednost p
How to use Rivastigmine 3M Health Care Ltd. 
Kako odstraniti transdermalni obliž Rivastigmin 3M Health Care Ltd.
PHARMACOLOGICAL PROPERTIES 
Imetnik dovoljenja za promet z zdravilom
The backing layer is transparent to translucent, labelled with “R10” in a repeated pattern. 
Krovna plast je prozorna do prosojna in označena z oznako
PHARMACEUTICAL PARTICULARS 
IMETNIK DOVOLJENJA ZA PROMET Z ZDRAVILOM
Take off your patch and tell your doctor straight away, if you notice any of the following side effects which could become serious: 
Če opazite katerega od naslednjih neželenih učinkov, ki bi lahko postali resni, takoj snemite
Carefully remove the existing patch before putting on a new one. 
Previdno odstranite obliž, ki je že na koži, in šele potem
- Carefully remove any existing patch before putting on a new one. 
- Preden namestite nov obliž, previdno odstranite prešnjega.
4.6 mg 
vrednost p a
Take off your patch and tell your doctor straight away, if you notice any of the side effects above. 
Če opazite katerega od zgoraj navedenih neželenih učinkov, takoj snemite obliž in obvestite svojega
Otherwise your doctor will restart your treatment on Rivastigmine 3M Health Care Ltd. 4.6 mg/24 h. 
Če zdravljenja s transdermalnim obližem niste prekinili za več kot tri dni, lahko nadaljujete z enakim odmerkom, v nasprotnem primeru pa vam bo zdravnik ponovno uvedel zdravilo Rivastigmin 3M Health Care Ltd. v odmerku 4,6 mg/24 h.
This summary was last updated in 04-2016. 
Povzetek je bil nazadnje posodobljen 04-2016.
The European Commission granted a marketing authorisation valid throughout the European Union for Bonviva on 23 February 2004. 
Evropska komisija je dovoljenje za promet z zdravilom Bonviva, veljavno po vsej Evropski uniji, izdala 23. februarja 2004.